PROGRESS

Docutech’s Solex® Named a 2024 Innovations Award Winner by the PROGRESS in Lending Association™

Retrieved on: 
Monday, April 8, 2024
Professional Services, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, REIT, Banking, PROGRESS, E-sign, EVault, Sale, Solex

Winners are chosen by PROGRESS in Lending’s executive team.

Key Points: 
  • Winners are chosen by PROGRESS in Lending’s executive team.
  • According to PROGRESS in Lending, Solex represents a significant leap forward in the mortgage industry by encompassing every stage of the mortgage process, from point-of-sale through post-closing.
  • Solex was also highlighted for its ability to operate without the need for extensive infrastructure on the lenders’ end.
  • Intentionally designed to be as configurable as possible, Solex allows lenders to build and display a unique solution for their borrowers.

InstaLend Corporation Co-founder Saurabh Shah Honored with the 2024 PROGRESS in Lending Next Gen Leader Award

Retrieved on: 
Tuesday, April 2, 2024
PROGRESS, Saurabh, Multimedia, Creativity, Growth, INC

NEW YORK, April 2, 2024 /PRNewswire-PRWeb/ -- InstaLend Corporation is thrilled to announce that its co-founder, Saurabh Shah, has been awarded the prestigious 2024 PROGRESS in Lending Next Gen Leader Award. This award recognizes Saurabh Shah's outstanding leadership and innovative contributions to the financial industry.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire-PRWeb/ -- InstaLend Corporation is thrilled to announce that its co-founder, Saurabh Shah , has been awarded the prestigious 2024 PROGRESS in Lending Next Gen Leader Award .
  • Saurabh Shah is a visionary entrepreneur who co-founded InstaLend Corporation with a mission to revolutionize real estate financial transactions.
  • The PROGRESS in Lending Next Gen Leader Award is a testament to Saurabh Shah's relentless drive, vision, and commitment to excellence.
  • For more information about the 2024 PROGRESS in Lending Next Gen Leader Award winners, please visit https://mymortgagemindset.com/the-2024-next-gen-leader-award-winners-are/ .

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Research, New Drug Application, American Heart Association, Investment, Obesity, Growth, EASD, Arrowhead Conference, Patient, Chronic kidney disease, Post hoc, Neuropathic pain, Marketing, Heart failure, Hypertension, Hypertrophic cardiomyopathy, Left ventricular hypertrophy, NDA, Express, PROGRESS, AAK1, Risk, Conference, HCM, Clinical trial, Neuroscience, Lexicon, FDA, Research and development, Cardiology, U.S. FDA, Medicare, Administration, Travel, Pharmaceutical industry

ET

Key Points: 
  • ET
    THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones.
  • “2023 was a pivotal year for Lexicon,” said Lonnel Coats, Lexicon’s chief executive officer.
  • Unless otherwise stated, all comparisons are for the fourth quarter and full year of 2023 compared to the fourth quarter and full year of 2022.
  • Revenues: Revenues for the fourth quarter and full year of 2023 were $0.7 million and $1.2 million, respectively, primarily from the commercialization of INPEFA.

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
PD, GSK, Arnon Rosenthal, Investment, Interest, ARIA, AbbVie, Webcast, Plasma, PET, MRI, Central nervous system, Traffic barrier, GPNMB, Cerebrospinal fluid, Breakthrough therapy, ALEC, Frontotemporal dementia, FTD, DSM-IV codes, European Medicines Agency, Food and Drug Administration, Canadian International Council, Brain, SAN, Total, LTE, Amyloid-related imaging abnormalities, Alector, ALS, AAIC, PROGRESS, ABC, Manuscript, Conference, Safety, Biomarker, Patent, CSF, Mutation, IND, Microglia, European Patent Convention, Insurance, PIN, FDA, Food, Risk, TREM2, Dementia, Disease, Pharmaceutical industry

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.

Edwards Lifesciences Reports Fourth Quarter Results

Retrieved on: 
Tuesday, February 6, 2024
Health, Medical Devices, Biometrics, Health Technology, General Health, Cardiology, Biotechnology, Acumen, EPS, SMART Recovery, Critical care, Growth, Mortality, PASCAL, Science, Aortic stenosis, PROGRESS, TAVR, Clinical trial, Research, Patient, FDA, Investment, M3, CE marking, Heart failure, Hypotension, Share repurchase, Completeness, U.S. FDA, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.
  • In the fourth quarter, Edwards remained focused on its key value drivers to unlock the significant long-term opportunity for patients: a portfolio of differentiated therapies; positive clinical trial results to support approvals and adoption; and favorable real-world clinical outcomes.
  • Research and development expenses in the fourth quarter grew 16 percent over the prior year to $270 million, or 17.6 percent of sales.
  • During the fourth quarter, the company repurchased $444 million of stock through a combination of a pre-established trading plan and accelerated share repurchase programs.

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Lithium, UGT, Risk, Digoxin, Shanda, Hypotension, FDA, SGLT1, Type 2 diabetes, Acute kidney injury, Congress, Pyelonephritis, Conference, Fever, Ketoacidosis, Pregabalin, Pregnancy, Pain, Assessment, Gabapentin, Tenderness, New Drug Application, Amber Grid, HCM, Common, SGLT2, PROGRESS, Hypertrophic cardiomyopathy, Diabetes, Kidney, Heart failure, Dialysis, History, Patient, Prescription, Type, Neuropathic pain, Webcast, Insulin, T2DM, EGFR, Erythema, T1DM, Hypoglycemia, Partnership, Contraindication, Diarrhea, NDA, Incidence, Swelling, Urinary tract infection, Hospital, Chronic kidney disease, Internationalized domain name, Metabolic acidosis, Creatinine, Growth, Lactation, Pharmaceutical industry

THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
  • “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
  • The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
  • Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
    Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Retrieved on: 
Thursday, November 30, 2023
T1DM, Food, FDA, AAK1, Type, Lexicon Pharmaceuticals, Patient, Dose-ranging study, Neuropathic pain, Extension, Trial of the century, Diagnosis, PROGRESS, Safety, T2DM, Fast Track, Pharmaceutical industry

THE WOODLANDS, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has enrolled the first patient in PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) studying LX9211, a potent, orally-delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1).

Key Points: 
  • PROGRESS will enroll adult patients with a diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) with moderate to severe DPNP.
  • The primary endpoint of PROGRESS is a reduction of Average Daily Pain Score (ADPS), consistent with the primary endpoint achieved in the successful RELIEF-DPN-1 Phase 2a proof-of-concept study and, informed by regulatory feedback, the primary endpoint planned for Phase 3 studies of LX9211 in DPNP.
  • The placebo-controlled treatment period of PROGRESS is intended to identify the optimal dosing for Phase 3 studies.
  • The open-label extension is expected to run in parallel with planned next-stage Phase 3 studies, supporting long-term safety requirements for regulatory approval.

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Retrieved on: 
Thursday, December 7, 2023
General Health, Health, Cardiology, TAVR, Corporation, NYSE, Tricuspid valve, Investment, Surgery, Percutaneous aortic valve replacement, Patient, CE marking, PASCAL, PROGRESS, Conference, CLASP, Aortic stenosis, Growth, Development, TCT, Edwards Lifesciences, Critical care, Pharmaceutical industry, Nursing, Pet industry, Management

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.
  • Continued progress across these areas will result in more patients diagnosed and treated with Edwards’ repair and replacement technologies, and a significant long-term growth opportunity.
  • Also in 2024, Edwards expects to accelerate its surgical mitral leadership with the global commercialization of its MITRIS RESILIA valve.
  • During the conference, Edwards’ management will reaffirm the company’s 2023 financial guidance and provide guidance for 2024.

EarnUp Celebrates Ten Year Anniversary Amid Increased Demand For Financial Wellness FinTech That Enables Debt & Mortgage Payment Automation

Retrieved on: 
Thursday, September 21, 2023
Fintech, Professional Services, Business, Finance, Acceleration, KeyBank, Workforce, PROGRESS, Benefit, Mortgage Bankers Association, PwC, Chicago Innovation Awards, St. Louis Fed Financial Stress Index, Work, Millennials, LendingTree, Thought, Organization, CNBC, Retirement, Bain Capital Ventures, Growth, Entrepreneurship, Ageing, Wells Fargo, Fortnight, Bank, Management

EarnUp, Inc. , a financial wellness fintech company, proudly celebrates ten years in business after tremendous growth and demand as more companies and financial institutions prioritize financial wellness.

Key Points: 
  • EarnUp, Inc. , a financial wellness fintech company, proudly celebrates ten years in business after tremendous growth and demand as more companies and financial institutions prioritize financial wellness.
  • The company was featured on HousingWire’s Tech100 for the first time this year, which recognizes companies and solutions revolutionizing the mortgage industry.
  • EarnUp was also named a 2023 Innovations Award winner from PROGRESS in Lending, and ranked on The Financial Technology Report’s 2023 Power 300 list .
  • According to Sheila G., an EarnUp customer from June 2023 , “EarnUp has been such a benefit to us.

U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine

Retrieved on: 
Tuesday, April 18, 2023
NORTH, PROGRESS, Migraine, Headache, ABBV, Clinical trial, AB toxin, Constipation, CGRP, Neurology, Virtual Private LAN Service, Patient, AbbVie, New England Center for Children, Nausea, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Food, Aroma compound

The approval makes QULIPTA the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine.

Key Points: 
  • The approval makes QULIPTA the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine.
  • Now, those with the most challenging to treat chronic migraine can also rely on QULIPTA to significantly reduce their migraine days," said Roopal Thakkar, senior vice president, chief medical officer, AbbVie.
  • "This approval makes AbbVie the only company with three treatments across the spectrum of migraine, including QULIPTA as a preventive treatment for both episodic and chronic migraine; BOTOX® (onabotulinumtoxinA), our foundational, first FDA-approved preventive treatment for chronic migraine; and UBRELVY® (ubrogepant), an acute treatment for migraine attacks."
  • These are critical factors neurologists and headache specialists consider when prescribing a treatment option, particularly for those with chronic migraine."